NCT00847054View on ClinicalTrials.gov

A Study of of MORAb-004 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Solid Tumor
Interventions
DRUG

MORAb-004 (monoclonal antibody to TEM1)

Intravenous administration

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

21205

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Lead Sponsor

Morphotek
All Listed Sponsors
lead

Morphotek

INDUSTRY